Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012158957 - KINASE MODULATION AND INDICATIONS THEREFOR

Publication Number WO/2012/158957
Publication Date 22.11.2012
International Application No. PCT/US2012/038417
International Filing Date 17.05.2012
IPC
A61K 31/437 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
CPC
A61K 2121/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
2121Preparations for use in therapy
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61K 31/4745
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
Applicants
  • PLEXXIKON INC. [US]/[US] (AllExceptUS)
  • ZHANG, Chao [US]/[US] (UsOnly)
  • BOLLAG, Gideon [US]/[US] (UsOnly)
  • HABETS, Gaston [US]/[US] (UsOnly)
  • ZHANG, Jiazhong [CN]/[US] (UsOnly)
  • IBRAHIM, Prabha N. [US]/[US] (UsOnly)
  • WU, Guoxian [US]/[US] (UsOnly)
Inventors
  • ZHANG, Chao
  • BOLLAG, Gideon
  • HABETS, Gaston
  • ZHANG, Jiazhong
  • IBRAHIM, Prabha N.
  • WU, Guoxian
Agents
  • REITER, Stephen E.
Priority Data
61/487,24917.05.2011US
61/522,65211.08.2011US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) KINASE MODULATION AND INDICATIONS THEREFOR
(FR) MODULATION DE KINASE ET INDICATIONS POUR CELLE-CI
Abstract
(EN)
The present invention relates to methods of using compounds active on oncogenic Flt3 kinase or Flt3 mutant, such as abnormally activated Flt3 kinase. In one aspect, the present invention provides methods of using compounds of Formula I and all the sub formulas and compounds as described herein that can be used therapeutically and/or prophylactically involving modulation of a Flt3 kinase, slich as an oncogenic Flt3 or Flt3 mutant. In one embodiment, the invention provides a method for treating a subject suffering from or at risk of an oncogenic Flt3 mediated disease or condition.
(FR)
La présente invention concerne des composés, des compositions et des procédés utiles pour le traitement de maladies ou affections médiées par Flt3. La présente invention concerne en outre des procédés pour moduler Flt3 (récepteur fms-like protéine tyrosine kinase 3).
Latest bibliographic data on file with the International Bureau